Zobrazeno 1 - 10 of 888 pro vyhledávání: '"Froidevaux, S."'
1
Akademický článek
Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity.
Autor: Hubler F; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Renneberg D; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Siendt H; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Stamm S; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Hilpert K; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Caroff E; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Delahaye S; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Froidevaux S; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Murphy MJ; Drug Discovery, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Mar 14; Vol. 67 (5), pp. 4100-4119. Date of Electronic Publication: 2024 Mar 04.
Zobrazit plný text záznamu
2
Akademický článek
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.
Autor: Lescop C; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Birker M; DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Brotschi C; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Bürki C; Chemistry Process R&D, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Morrison K; DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Froidevaux S; DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Delahaye S; Preclinical DMPK, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Nayler O; DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Bolli MH; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2397-2424. Date of Electronic Publication: 2024 Feb 13.
Zobrazit plný text záznamu
3
Akademický článek
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold.
Autor: Lescop C; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Brotschi C; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Williams JT; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Sager CP; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Birker M; DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Morrison K; DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Froidevaux S; DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Delahaye S; Preclinical DMPK, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Nayler O; DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland., Bolli MH; DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2379-2396. Date of Electronic Publication: 2024 Feb 13.
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.
Autor: Meyer EA; Chemistry Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Äänismaa P; DMPK, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Ertel EA; Electrophysiology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Hühn E; DMPK, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Strasser DS; Translational Biomarkers, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Rey M; Cardiovascular Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Murphy MJ; Biology Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Martinic MM; Pharmacology Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Pouzol L; Pharmacology Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Froidevaux S; Idorsia Pharmaceuticals Ltd, Bendorf 68480, France., Keller MP; Biology Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland., Caroff E; Chemistry Immunology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, Allschwil 4123, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2023 Mar 23; Vol. 66 (6), pp. 4179-4196. Date of Electronic Publication: 2023 Mar 08.
Zobrazit plný text záznamu
6
Akademický článek
Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.
Autor: Caroff E; Drug Discovery Chemistry Immunology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Meyer EA; Drug Discovery Chemistry Immunology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Äänismaa P; DMPK, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Froidevaux S; Private Location, Bendorf 68480, France., Keller M; Drug Discovery Biology Immunology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Piali L; Immunology, Infectious Diseases and Ophthalmology, pRED Roche, Basel 4070, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Sep 08; Vol. 65 (17), pp. 11533-11549. Date of Electronic Publication: 2022 Aug 15.
Zobrazit plný text záznamu
7
Akademický článek
Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.
Autor: Meyer EA; Drug Discovery Chemistry Immunology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Äänismaa P; DMPK, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Froidevaux S; Private location, Bendorf 68480, France., Keller M; Drug Discovery Biology Immunology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland., Piali L; Immunology, Infectious Diseases and Ophthalmology, pRED Roche, Basel 4070, Switzerland., Caroff E; Drug Discovery Chemistry Immunology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Sep 08; Vol. 65 (17), pp. 11513-11532. Date of Electronic Publication: 2022 Aug 10.
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Adoptive transfer of the generalized lymphoproliferative disease (gld) syndrome in nude beige mice.
Autor: Froidevaux, S.1, Rosenblatt, N.1, Loor, F.1
Publikováno v: Immunology. Apr92, Vol. 75 Issue 4, p693-699. 7p.
Zobrazit plný text záznamu
10
Akademický článek
Cenerimod, a selective S1P 1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren's syndrome.
Autor: Gerossier E; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Nayar S; Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, College of Medical & Dental Sciences, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, Birmingham, UK., Froidevaux S; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Smith CG; Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, College of Medical & Dental Sciences, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, Birmingham, UK., Runser C; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Iannizzotto V; Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, College of Medical & Dental Sciences, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, Birmingham, UK., Vezzali E; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Pierlot G; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Mentzel U; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Murphy MJ; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland. mark.murphy@idorsia.com., Martinic MM; Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, Switzerland. marianne.martinic@idorsia.com., Barone F; Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, College of Medical & Dental Sciences, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, Birmingham, UK.; Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2021 Nov 29; Vol. 23 (1), pp. 289. Date of Electronic Publication: 2021 Nov 29.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje